KEY TAKEAWAYS
- The HALO study aimed to assess HRD prevalence in HGSOC, PPC, and FTC across Asia, MEA, and Russia.
- The result concluded the real-world study underscores HRD prevalence variation and the need for diverse testing in resource-limited settings.
The prevalence of Homologous Recombination Deficiency (HRD) and the application of diverse HRD testing kits remain inadequately defined across various geographical regions. Understanding these aspects is crucial for comprehending the landscape of HRD-associated conditions and optimizing diagnostic strategies globally.
Herein, in the HALO study, Salha B. Bujassoum and other researchers investigated HRD prevalence in patients diagnosed with high-grade serous or endometrioid ovarian cancer (HGSOC/HGEOC), primary peritoneal cancer (PPC), and/or fallopian tube cancer (FTC) across Asia, the Middle East, Africa (MEA), and Russia.
The multinational cross-sectional study included adult women who consented and were newly diagnosed with stage III or IV HGSOC/HGEOC, PPC, and/or FTC having formalin-fixed paraffin tumors collected within 120 days of enrollment were utilized. The study presents the prevalence of HRD with genomic instability (GI), excluding tumor BRCA1/2 mutations (tBRCA1/2m) and specifically focusing on cases with tBRCA1/2m using next-generation sequencing (NGS).
About 734 participants with a median age of 59.0 years (ranging from 23.0 to 89.0 years) were enrolled across Asia (n=76), the MEA (n=195), and Russia (n=463). The majority of participants (88.1%) reported never having smoked, while 83.9% had experienced menopause, and 78.8% were multiparous. About 34.1% had a family history of cancer. Among the participants, 92.9% had the primary tumor located in the ovaries, followed by PPC in 4.1% and FTC in 3.0%.
The HRD status was assessed in 662 participants, revealing that 56.0% (371 individuals) tested positive for HRD. Specifically, 30.8% (204) exhibited a high score in the GI region, excluding tBRCA1/2 mutations, and 25.2% (167) had tBRCA1/2 mutations. The prevalence of HRD in Asia, MEA, and Russia was 52.0%, 52.2%, and 58.5%, respectively. Commercial kits were commonly utilized for HRD testing in 56.5% of cases, with Amoydx being the predominant choice (88.0%, 329 cases).
The result concluded that the real-world investigation reveals the prevalence of HRD in a substantial patient cohort, ranging from 52.0% to 58.5% across the three geographical study regions. The findings underscore the pressing requirement for comprehensive data on biomarker testing and emphasize the practical value of diverse HRD testing kits in real-world scenarios, particularly in resource-constrained settings, to guide informed treatment choices.
This study is sponsored by AstraZeneca.
Source: https://cslide.ctimeetingtech.com/asia2023/attendee/confcal/show/session/28
Clinical Trial: https://clinicaltrials.gov/study/NCT04991051
Tyulyandina A, Bujassoum SB, Mokhtar M, et al. “Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: Results from the international HALO study.” Presented at ESMO ASIA Congress 2023. (Abstract: 2850).
